FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135294709> ?p ?o ?g. }

• W3135294709 endingPage "417" @default.
• W3135294709 startingPage "401" @default.
• W3135294709 abstract "For decades, anticancer targeted therapies have been designed to inhibit kinases or other enzyme classes and have profoundly benefited many patients. However, novel approaches are required to target transcription factors, scaffolding proteins and other proteins central to cancer biology that typically lack catalytic activity and have remained mostly recalcitrant to drug development. The selective degradation of target proteins is an attractive approach to expand the druggable proteome, and the selective oestrogen receptor degrader fulvestrant served as an early example of this concept. Following a long and tragic history in the clinic, the immunomodulatory imide drug (IMiD) thalidomide was discovered to exert its therapeutic activity via a novel and unexpected mechanism of action: targeting proteins to an E3 ubiquitin ligase for subsequent proteasomal degradation. This discovery has paralleled and directly catalysed myriad breakthroughs in drug development, leading to the rapid maturation of generalizable chemical platforms for the targeted degradation of previously undruggable proteins. Decades of clinical experience have established front-line roles for thalidomide analogues, including lenalidomide and pomalidomide, in the treatment of haematological malignancies. With a new generation of ‘degrader’ drugs currently in development, this experience provides crucial insights into class-wide features of degraders, including a unique pharmacology, mechanisms of resistance and emerging therapeutic opportunities. Herein, we review these past experiences and discuss their application in the clinical development of novel degrader therapies. The discovery that the anticancer activity of thalidomide and its analogues, such as lenalidomide, reflects drug-induced degradation of specific target proteins has heightened interest in novel ‘degrader’ drugs. Herein, the authors review the wide and expanding use of thalidomide analogues in the treatment of multiple cancers and outline how lessons learned from this experience, particularly with lenalidomide, can guide the clinical development of new targeted protein degradation platforms." @default.
• W3135294709 created "2021-03-15" @default.
• W3135294709 creator A5049292869 @default.
• W3135294709 creator A5070668676 @default.
• W3135294709 creator A5079209072 @default.
• W3135294709 date "2021-03-02" @default.
• W3135294709 modified "2023-10-04" @default.
• W3135294709 title "Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide" @default.
• W3135294709 cites W1043004949 @default.
• W3135294709 cites W1512690422 @default.
• W3135294709 cites W1521738036 @default.
• W3135294709 cites W1527383154 @default.
• W3135294709 cites W1587476434 @default.
• W3135294709 cites W1587685635 @default.
• W3135294709 cites W1597238753 @default.
• W3135294709 cites W1628369270 @default.
• W3135294709 cites W1807588734 @default.
• W3135294709 cites W1858039550 @default.
• W3135294709 cites W1898969431 @default.
• W3135294709 cites W1920222387 @default.
• W3135294709 cites W1965813899 @default.
• W3135294709 cites W1969648097 @default.
• W3135294709 cites W1970400561 @default.
• W3135294709 cites W1973888964 @default.
• W3135294709 cites W1973999018 @default.
• W3135294709 cites W1976899534 @default.
• W3135294709 cites W1979977043 @default.
• W3135294709 cites W1980451195 @default.
• W3135294709 cites W1981403111 @default.
• W3135294709 cites W1982166691 @default.
• W3135294709 cites W1984365472 @default.
• W3135294709 cites W1985147506 @default.
• W3135294709 cites W1985864219 @default.
• W3135294709 cites W1989595541 @default.
• W3135294709 cites W1990288154 @default.
• W3135294709 cites W1991998373 @default.
• W3135294709 cites W1992538067 @default.
• W3135294709 cites W1992776819 @default.
• W3135294709 cites W1994013901 @default.
• W3135294709 cites W1994721812 @default.
• W3135294709 cites W1997952190 @default.
• W3135294709 cites W1998384592 @default.
• W3135294709 cites W2000130439 @default.
• W3135294709 cites W2004543856 @default.
• W3135294709 cites W2005530496 @default.
• W3135294709 cites W2007644267 @default.
• W3135294709 cites W2009443185 @default.
• W3135294709 cites W2014018534 @default.
• W3135294709 cites W2015345028 @default.
• W3135294709 cites W2018947211 @default.
• W3135294709 cites W2020445243 @default.
• W3135294709 cites W2021954218 @default.
• W3135294709 cites W2022773559 @default.
• W3135294709 cites W2024857098 @default.
• W3135294709 cites W2025030626 @default.
• W3135294709 cites W2025656486 @default.
• W3135294709 cites W2027774332 @default.
• W3135294709 cites W2032571438 @default.
• W3135294709 cites W2033024649 @default.
• W3135294709 cites W2033556677 @default.
• W3135294709 cites W2036985459 @default.
• W3135294709 cites W2039186983 @default.
• W3135294709 cites W2040329520 @default.
• W3135294709 cites W2042479316 @default.
• W3135294709 cites W2048365283 @default.
• W3135294709 cites W2048722552 @default.
• W3135294709 cites W2049005444 @default.
• W3135294709 cites W2053685717 @default.
• W3135294709 cites W2059311525 @default.
• W3135294709 cites W2059837228 @default.
• W3135294709 cites W2060496777 @default.
• W3135294709 cites W2065974097 @default.
• W3135294709 cites W2068412287 @default.
• W3135294709 cites W2074423820 @default.
• W3135294709 cites W2075017432 @default.
• W3135294709 cites W2076744879 @default.
• W3135294709 cites W2081045803 @default.
• W3135294709 cites W2081870738 @default.
• W3135294709 cites W2082177829 @default.
• W3135294709 cites W2086278185 @default.
• W3135294709 cites W2087607698 @default.
• W3135294709 cites W2091773528 @default.
• W3135294709 cites W2094823633 @default.
• W3135294709 cites W2095599841 @default.
• W3135294709 cites W2095669071 @default.
• W3135294709 cites W2097331346 @default.
• W3135294709 cites W2100483340 @default.
• W3135294709 cites W2101603234 @default.
• W3135294709 cites W2106742754 @default.
• W3135294709 cites W2107384529 @default.
• W3135294709 cites W2113101033 @default.
• W3135294709 cites W2114492363 @default.
• W3135294709 cites W2115859409 @default.
• W3135294709 cites W2116549767 @default.
• W3135294709 cites W2117010543 @default.
• W3135294709 cites W2119601553 @default.
• W3135294709 cites W2119967034 @default.
• W3135294709 cites W2120590293 @default.

• next